Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 100,713 Shares of Company Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $90.54, for a total value of $9,118,555.02. Following the completion of the sale, the executive vice president directly owned 29,276 shares in the company, valued at $2,650,649.04. This represents a 77.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total value of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total value of $1,605,085.44.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.14, for a total value of $230,848.54.

Dianthus Therapeutics Price Performance

DNTH opened at $92.48 on Friday. The business has a 50 day simple moving average of $88.77 and a 200-day simple moving average of $86.36. The stock has a market capitalization of $5.21 billion, a P/E ratio of -23.18 and a beta of 1.47. Dianthus Therapeutics, Inc. has a 12 month low of $34.29 and a 12 month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The firm had revenue of $1.21 million for the quarter, compared to the consensus estimate of $0.46 million. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DNTH. Truist Financial boosted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Raymond James Financial reiterated a “strong-buy” rating and issued a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday, November 5th. Wedbush raised their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Finally, Citigroup assumed coverage on shares of Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $128.77.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Walleye Capital LLC purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at about $1,743,000. SummitTX Capital L.P. lifted its holdings in shares of Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock valued at $8,396,000 after purchasing an additional 12,118 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Dianthus Therapeutics by 155.5% in the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after purchasing an additional 24,697 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $25,036,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Dianthus Therapeutics in the second quarter valued at approximately $34,587,464. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.